References

[1] Ho, C. K., & Habib, F. K. (2011). Estrogen and androgen signaling in the pathogenesis of BPH. Nature Reviews Urology, 8(1), 29-41.

[2] McConnell, J. D. (1995). Benign prostatic hyperplasia: hormonal treatment. Urologic Clinics of North America, 22(2), 387-400.

[3] Wang, Z., & Olumi, A. F. (2011). Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation, 82(4-5), 261-271.

[4] Ueda, T., Ichikawa, T., Tamaru, J. I., Mikata, A., Akakura, K., Akimoto, S., ... & Shimazaki, J. (1996). Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. The American journal of pathology, 149(5), 1435.

[5] Jean Ho, P., & Baxter, R. C. (1997). Insulin‐like growth factor‐binding protein‐2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clinical endocrinology, 46(3), 333-342.